Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Jacobson

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Alimentary Pharmacology & Therapeutics|June 30, 2020
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practicesZobair M Younossi, Kathleen E Corey, Naim Alkhouri, et al.
The American Journal of Gastroenterology|August 30, 2019
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of LifeZobair M Younossi, Maria Stepanova, Eric J Lawitz, et al.
Cancer|July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BW Ray Kim, Rohit Loomba, Thomas Berg, et al.
Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Journal of Hepatology|January 22, 2017
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcomeStefan Zeuzem, Masashi Mizokami, Stephen Pianko, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Alimentary Pharmacology & Therapeutics|June 30, 2020
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practicesZobair M Younossi, Kathleen E Corey, Naim Alkhouri, et al.
The American Journal of Gastroenterology|August 30, 2019
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of LifeZobair M Younossi, Maria Stepanova, Eric J Lawitz, et al.
Cancer|July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BW Ray Kim, Rohit Loomba, Thomas Berg, et al.
Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Journal of Hepatology|January 22, 2017
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcomeStefan Zeuzem, Masashi Mizokami, Stephen Pianko, et al.
Pageof 5